Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

At the Cutting Edge

Advanced Release (accepted, unedited manuscript)

The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines

Zandee W.T. · de Herder W.W.

Author affiliations

Endocrinology Sector, Department of Internal Medicine, ENETS Centre of Excellence, Erasmus MC and Erasmus MC Cancer Institute, Rotterdam, the Netherlands

Related Articles for ""

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 0.00 *
EUR 0.00 *
USD 0.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of At the Cutting Edge

Received: July 27, 2017
Accepted: December 05, 2017
Published online: January 10, 2018

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: https://www.karger.com/NEN

Abstract

In 2016, the third version of guidelines for the diagnosis and treatment of neuroendocrine tumors (NETs) has been published by the European Neuroendocrine Tumor Society (ENETS). These guidelines reflect the progress in treatment of NETs, and by comparing the newest guidelines with the first guidelines of 2001, this progress can be clearly recognized. Diagnostic accuracy has been increased by the introduction of PET-CT with Ga-labelled somatostatin analogs, and multiple new treatments and treatment schedules have been developed, like peptide receptor radiotherapy with radiolabeled somatostatin analogs, or targeted therapies. Evidence and indications for these therapies are discussed in the ENETS guidelines. In this review, we aim to show the progress in NET diagnosis and treatment on the basis of the advances in the guidelines, but also to discuss the unsolved questions and unmet needs which still remain.

© 2018 The Author(s) Published by S. Karger AG, Basel


References

  1. http://www.enets.org/what_is_enets.html.
  2. Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B: Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol 2001; 37: 8–17.
  3. Vezzosi D, Bennet A, Courbon F, Caron P: Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism. Clin Endocrinol (Oxf) 2008; 68: 904–911.
  4. Plockinger U, Rindi G, Arnold R, Eriksson B, et al: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80: 394–424.
  5. Sundin A, Arnold R, Baudin E, Cwikla JB, et al: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging. Neuroendocrinology 2017; 105: 212–244.
  6. Elias D, Lefevre JH, Duvillard P, Goere D, Dromain C, Dumont F, Baudin E: Hepatic metastases from neuroendocrine tumors with a “thin slice” pathological examination: they are many more than you think. Ann Surg 2010; 251: 307–310.
  7. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW: Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 1: 242–244.
  8. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW: Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 2003; 10: 451–458.
  9. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, Mignon M, le Guludec D: Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997; 38: 853–858.
  10. Balon HR, Brown TL, Goldsmith SJ, Silberstein EB, et al: The SNM practice guideline for somatostatin receptor scintigraphy 2.0. J Nucl Med Technol 2011; 39: 317–324.
  11. Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, Donohoe KJ; Society of Nuclear Medicine: Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med 2001; 42: 1134–1138.
  12. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, Schilling T, Haufe S, Herrmann T, Haberkorn U: Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34: 1617–1626.
  13. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ: 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508–518.
  14. Geijer H, Breimer LH: Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2013; 40: 1770–1780.
  15. Johnbeck CB, Knigge U, Kjaer A: PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol 2014; 10: 2259–2277.
  16. Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W: Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol 2014; 55: 389–398.
  17. Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, Allegri V, Rubello D, Montini G, Franchi R, Fanti S: (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010; 37: 722–727.
  18. Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ: Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009; 50: 1214–1221.
  19. Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C: 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 2011; 52: 1864–1870.
  20. Velikyan I, Sundin A, Sorensen J, Lubberink M, Sandstrom M, Garske-Roman U, Lundqvist H, Granberg D, Eriksson B: Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med 2014; 55: 204–210.
  21. Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, Hansen CP, Hojgaard L, Kjaer A: Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med 2010; 51: 704–712.
  22. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A: 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010; 16: 978–985.
  23. Kashyap R, Hofman MS, Michael M, Kong G, Akhurst T, Eu P, Zannino D, Hicks RJ: Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2015; 42: 176–185.
  24. Perren A, Couvelard A, Scoazec JY, Costa F, et al: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. Neuroendocrinology 2017; 105: 196–200.
  25. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S: The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39: 707–712.
  26. Pape UF, Niederle B, Costa F, Gross D, et al: ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas). Neuroendocrinology 2016; 103: 144–152.
  27. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B: TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451: 757–762.
  28. Rindi G, Kloppel G, Alhman H, Caplin M, et al: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395–401.
  29. Pape UF, Jann H, Muller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Rocken C, Rindi G, Wiedenmann B: Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008; 113: 256–265.
  30. Strosberg J, Nasir A, Coppola D, Wick M, Kvols L: Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol 2009; 40: 1262–1268.
  31. Dhall D, Mertens R, Bresee C, Parakh R, Wang HL, Li M, Dhall G, Colquhoun SD, Ines D, Chung F, Yu R, Nissen NN, Wolin E: Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors. Hum Pathol 2012; 43: 489–495.
  32. Lloyd RV, Osamura RY, Klöppel G, Rosai J, Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H (eds), World Health Organization, International Agency for Research on Cancer: WHO Classification of Tumours of Endocrine Organs, ed 4. Geneva, World Health Organization, 2017.
  33. Tang LH, Basturk O, Sue JJ, Klimstra DS: A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol 2016; 40: 1192–1202.
  34. Rindi G, Falconi M, Klersy C, Albarello L, et al: TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 2012; 104: 764–777.
  35. Oberg K: The genetics of neuroendocrine tumors. Semin Oncol 2013; 40: 37–44.
  36. Partelli S, Bartsch DK, Capdevila J, Chen J, et al: ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. Neuroendocrinology 2017; 105: 255–265.
  37. Oberg K, Couvelard A, Delle Fave G, Gross D, et al: ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers. Neuroendocrinology 2017; 105: 201–211.
  38. Kaltsas G, Caplin M, Davies P, Ferone D, et al: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology 2017; 105: 245–254.
  39. Wiedenmann B, Jensen RT, Mignon M, Modlin CI, Skogseid B, Doherty G, Oberg K: Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg 1998; 22: 309–318.
  40. Sadot E, Reidy-Lagunes DL, Tang LH, Do RK, Gonen M, D’Angelica MI, DeMatteo RP, Kingham TP, Groot Koerkamp B, Untch BR, Brennan MF, Jarnagin WR, Allen PJ: Observation versus resection for small asymptomatic pancreatic neuroendocrine tumors: a matched case-control study. Ann Surg Oncol 2016; 23: 1361–1370.
  41. Gaujoux S, Partelli S, Maire F, D’Onofrio M, Larroque B, Tamburrino D, Sauvanet A, Falconi M, Ruszniewski P: Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 2013; 98: 4784–4789.
  42. Asymptomatic Small Pancreatic Endocrine Neoplasms. NCT03084770, 2017.
  43. Norton JA, Fraker DL, Alexander HR, Jensen RT: Value of surgery in patients with negative imaging and sporadic Zollinger-Ellison syndrome. Ann Surg 2012; 256: 509–517.
  44. Giovinazzo F, Butturini G, Monsellato D, Malleo G, Marchegiani G, Bassi C: Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma. Updates Surg 2013; 65: 19–24.
  45. Weber HC, Venzon DJ, Lin JT, Fishbein VA, Orbuch M, Strader DB, Gibril F, Metz DC, Fraker DL, Norton JA, et al: Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108: 1637–1649.
  46. Yu F, Venzon DJ, Serrano J, Goebel SU, Doppman JL, Gibril F, Jensen RT: Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999; 17: 615–630.
  47. Falconi M, Eriksson B, Kaltsas G, Bartsch DK, et al: ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2016; 103: 153–171.
  48. Ruszniewski P, Podevin P, Cadiot G, Marmuse JP, Mignon M, Vissuzaine C, Bonfils S, Lehy T: Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type I multiple endocrine neoplasia. Pancreas 1993; 8: 295–304.
  49. Mullen JT, Savarese DM: Carcinoid tumors of the appendix: a population-based study. J Surg Oncol 2011; 104: 41–44.
  50. Moertel CG, Weiland LH, Nagorney DM, Dockerty MB: Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987; 317: 1699–1701.
  51. Fornaro R, Frascio M, Sticchi C, De Salvo L, Stabilini C, Mandolfino F, Ricci B, Gianetta E: Appendectomy or right hemicolectomy in the treatment of appendiceal carcinoid tumors? Tumori 2007; 93: 587–590.
  52. Bokey EL, Chapuis PH, Fung C, Hughes WJ, Koorey SG, Brewer D, Newland RC: Postoperative morbidity and mortality following resection of the colon and rectum for cancer. Dis Colon Rectum 1995; 38: 480–486; discussion 486–487.
  53. Niederle B, Pape UF, Costa F, Gross D, et al: ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology 2016; 103: 125–138.
  54. Capurso G, Rinzivillo M, Bettini R, Boninsegna L, Delle Fave G, Falconi M: Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. Br J Surg 2012; 99: 1480–1486.
  55. Pavel M, O’Toole D, Costa F, Capdevila J, et al: ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016; 103: 172–185.
  56. Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, Oberg K: Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol (Stockholm) 1997; 36: 607–614.
  57. Eriksson B, Janson ET, Bax ND, Mignon M, Morant R, Opolon P, Rougier P, Oberg KE: The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours. Digestion 1996; 57(suppl 1):77–80.
  58. Eriksson B, Renstrup J, Imam H, Oberg K: High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997; 8: 1041–1044.
  59. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656–4663.
  60. Caplin ME, Pavel M, Ruszniewski P: Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371: 1556–1557.
  61. Pavel M, Valle JW, Eriksson B, Rinke A, et al: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy – Biotherapy and Novel Targeted Agents. Neuroendocrinology 2017; 105: 266–280.
  62. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124–2130.
  63. Strosberg J, El-Haddad G, Wolin E, Hendifar A, et al: Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 376: 125–135.
  64. Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, et al: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology 2017; 105: 295–309.
  65. Pavel M, Baudin E, Couvelard A, Krenning E, et al: ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95: 157–176.
  66. Yao JC, Shah MH, Ito T, Bohas CL, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514–523.
  67. Pavel ME, Hainsworth JD, Baudin E, Peeters M, et al: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378: 2005–2012.
  68. Yao JC, Fazio N, Singh S, Buzzoni R, et al: Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387: 968–977.
  69. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501–513.
  70. Platanias LC: Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5: 375–386.
  71. Oberg K, Funa K, Alm G: Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983; 309: 129–133.
  72. Oberg K, Eriksson B: The role of interferons in the management of carcinoid tumours. Br J Haematol 1991; 79(suppl 1):74–77.
  73. Oberg K: Interferon-alpha versus somatostatin or the combination of both in gastro- enteropancreatic tumours. Digestion 1996; 57(suppl 1):81–83.
  74. Eriksson B, Kloppel G, Krenning E, Ahlman H, et al: Consensus guidelines for the management of patients with digestive neuroen­docrine tumors–well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 2008; 87: 8–19.
  75. Pavel ME, Baum U, Hahn EG, Schuppan D, Lohmann T: Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res 2006; 26: 8–13.
  76. Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, et al: ENETS Consensus Guidelines for High-Grade Gastroenteropancreat ic Neuroendocrine Tumors and Neuroen­docrine Carcinomas. Neuroendocrinology 2016; 103: 186–194.
  77. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U: Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2012; 24: 152–160.
  78. Moertel CG, Kvols LK, O’Connell MJ, Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227–232.
  79. Moertel CG, Hanley JA, Johnson LA: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980; 303: 1189–1194.
  80. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG; Eastern Cooperative Oncology Group: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005; 23: 4897–4904.
  81. Dahan L, Bonnetain F, Rougier P, Raoul JL, et al: Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Relat Cancer 2009; 16: 1351–1361.
  82. Ducreux M, Adenis A, Pignon JP, Francois E, Chauffert B, Ichante JL, Boucher E, Ychou M, Pierga JY, Montoto-Grillot C, Conroy T: Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). Eur J Cancer 2013; 49: 1236–1245.
  83. de Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreux M, Boige V, Lassau N, Marteau V, Lasser P, Roche A: Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000; 175: 1619–1625.
  84. de Baere T, Deschamps F, Tselikas L, Ducreux M, Planchard D, Pearson E, Berdelou A, Leboulleux S, Elias D, Baudin E: GEP-NETS update: interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol 2015; 172:R151–R166.
  85. Devcic Z, Rosenberg J, Braat AJ, Techasith T, Banerjee A, Sze DY, Lam MG: The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. J Nucl Med 2014; 55: 1404–1410.
  86. Maire F, Lombard-Bohas C, O’Toole D, Vullierme MP, Rebours V, Couvelard A, Pelletier AL, Zappa M, Pilleul F, Hentic O, Hammel P, Ruszniewski P: Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study. Neuroendocrinology 2012; 96: 294–300.
  87. Qaseem A, Snow V, Owens DK, Shekelle P, et al: The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. Ann Intern Med 2010; 153: 194–199.
  88. Efficacy and safety of everolimus and (STZ-5FU) given one upfront the other upon progression in advanced pNET (SEQTOR). https://clinicaltrialsgov/ct2/show/study/NCT02246127?show_locs=Y#locn.

Article / Publication Details

First-Page Preview
Abstract of At the Cutting Edge

Received: July 27, 2017
Accepted: December 05, 2017
Published online: January 10, 2018

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: https://www.karger.com/NEN


Open Access License / Drug Dosage / Disclaimer

This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.